Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis
- PMID: 12481159
- DOI: 10.1159/000066755
Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis
Abstract
Cancers of the gastrointestinal tract, including the liver, bile ducts, and pancreas, constitute the largest group of malignant tumors. Colorectal cancer is one of the most common neoplastic diseases in Western countries and one of the leading causes of cancer-related deaths. Inactivation of the adenomatous polyposis coli (APC) tumor-suppressor gene during early adenoma formation is thought to be the first genetic event in the process of colorectal carcinogenesis followed by mutations in oncogenes like K-Ras and tumor-suppressor genes like p53. Identification of the interaction of APC with the proto-oncogene beta-catenin has linked colorectal carcinogenesis to the Wnt-signal transduction pathway. The main function of APC is thought to be the regulation of free beta-catenin in concert with the glycogen synthase kinase 3beta (GSK-3beta) and Axin proteins. Loss of APC function, inactivation of Axin or activating beta-catenin mutations result in the cellular accumulation of beta-catenin. Upon translocation to the nucleus beta-catenin serves as an activator of T-cell factor (Tcf)-dependent transcription leading to an increased expression of several specific target genes including c-Myc, cyclin D1, MMP-7, and ITF-2. While APC mutations are almost exclusively found in colorectal cancers, deregulation of Wnt/beta-catenin/Tcf signaling is also common in other gastrointestinal and extra-gastrointestinal human cancers. In a fraction of hepatocellular carcinomas the Wnt pathway is deregulated by inactivation of Axin or stabilizing mutations of beta-catenin. The majority of hepatoblastomas and a group of gastric cancers also carry beta-catenin mutations. Clearly, this pathway harbors great potential for future applications in cancer diagnostics, staging, and therapy.
Copyright 2002 S. Karger AG, Basel
Similar articles
-
ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.Cancer Cell. 2002 Mar;1(2):145-55. doi: 10.1016/s1535-6108(02)00035-1. Cancer Cell. 2002. PMID: 12086873
-
A possible role for the WNT-1 pathway in oral carcinogenesis.Crit Rev Oral Biol Med. 2001;12(2):152-65. doi: 10.1177/10454411010120020501. Crit Rev Oral Biol Med. 2001. PMID: 11345525 Review.
-
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.Nat Genet. 2000 Mar;24(3):245-50. doi: 10.1038/73448. Nat Genet. 2000. PMID: 10700176
-
The Yin-Yang of TCF/beta-catenin signaling.Adv Cancer Res. 2000;77:1-24. doi: 10.1016/s0065-230x(08)60783-6. Adv Cancer Res. 2000. PMID: 10549354 Review.
-
Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level.Genes Cells. 1998 Jun;3(6):395-403. doi: 10.1046/j.1365-2443.1998.00198.x. Genes Cells. 1998. PMID: 9734785
Cited by
-
Microcystin-leucine arginine induces the proliferation of cholangiocytes and cholangiocarcinoma cells through the activation of the Wnt/β-catenin signaling pathway.Heliyon. 2024 Apr 26;10(9):e30104. doi: 10.1016/j.heliyon.2024.e30104. eCollection 2024 May 15. Heliyon. 2024. PMID: 38720699 Free PMC article.
-
miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review.J Egypt Natl Canc Inst. 2024 Apr 29;36(1):16. doi: 10.1186/s43046-024-00220-8. J Egypt Natl Canc Inst. 2024. PMID: 38679648 Review.
-
PNU-74654 Induces Cell Cycle Arrest and Inhibits EMT Progression in Pancreatic Cancer.Medicina (Kaunas). 2023 Aug 24;59(9):1531. doi: 10.3390/medicina59091531. Medicina (Kaunas). 2023. PMID: 37763649 Free PMC article.
-
Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening.BMC Med. 2023 Sep 4;21(1):336. doi: 10.1186/s12916-023-03034-y. BMC Med. 2023. PMID: 37667332 Free PMC article.
-
Galectin-3 Mediates Tumor Progression in Astrocytoma by Regulating Glycogen Synthase Kinase-3β Activity.Curr Issues Mol Biol. 2023 Apr 19;45(4):3591-3602. doi: 10.3390/cimb45040234. Curr Issues Mol Biol. 2023. PMID: 37185758 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous